...
首页> 外文期刊>Current drug delivery >Development of Novel Combined Time and pH-Dependent Based Drug Delivery Systems for Targeting 5-Fluorouracil to the Colon.
【24h】

Development of Novel Combined Time and pH-Dependent Based Drug Delivery Systems for Targeting 5-Fluorouracil to the Colon.

机译:针对5-氟尿嘧啶靶向结肠的新型结合时间和pH依赖的新型药物递送系统的开发。

获取原文
获取原文并翻译 | 示例

摘要

The present work is aimed to develop new oral drug delivery systems of 5-fluorouracil for the treatment of colorectal cancer by using hydrophilic swellable polymer hydroxy propyl methyl cellulose (HPMC) and pH responsive soluble polymer Eudragit L100 (ED) as coating materials. Core tablets containing 50mg of 5-fluorouracil were prepared by direct compression. The core tablets compression coated with different ratios (9:1, 8:2, 7:3, 6:4 and 5:5) of HPMC and ED with a coat weight of 300 and 400mg. All the formulations were evaluated for the hardness, friability, drug content uniformity and in vitro drug release studies in media of different pH 1.2, 7.4 and 6.8. The formulations released 0 to 7% of the drug in physiological environment of stomach and small intestine depending upon proportion of HPMC and ED used in the coat. Among the different ratios used for coating with HPMC:ED combination, ratio 9:1 gave the best release profile with the coat weight of 300mg (1.34% in the initial 5h and 87% in 24 h). Further increase in the coat weight to 400mg with different ratios of 9:1, 8:2, 7:3, 6:4 and 5:5 led to drug release of 0%, 0%, 0%, 3.47% and 6.25%, respectively in the initial 5 h and 73.52%, 87.03%, 92.18%, 96.33% and 97.61%, respectively, in 24 h. Thus, based on the results of in vitro drug release studies, the ratio 7:3 with a coat weight of 400mg was found to be suitable for targeting 5-fluorouracil to the colon without being released in physiological environment of stomach and small intestine. The formulation showed no change in physical appearance, drug content or in vitro release pattern after storage at 40( degrees ) C / 75% RH for 3 months. The release of 5-fluorouracil from developed formulation was directly proportional to amount of ED used in the coat. The DSC and FTIR studies indicated no possibility of interaction between 5-fluorouracil and excipients.
机译:本工作旨在通过使用亲水性可溶胀聚合物羟丙基甲基甲基纤维素(HPMC)和pH响应可溶性聚合物Eudragit L100(ED)作为涂层材料,开发用于治疗大肠癌的新型5-氟尿嘧啶口服药物输送系统。通过直接压制制备含有50mg 5-氟尿嘧啶的核心片剂。压片以不同比例(9:1、8:2、7:3、6:4和5:5)的HPMC和ED压片,包衣重量为300和400mg。在不同pH 1.2、7.4和6.8的介质中评估了所有制剂的硬度,脆性,药物含量均匀性和体外药物释放研究。根据在外套中使用的HPMC和ED的比例,制剂在胃和小肠的生理环境中释放0至7%的药物。在使用HPMC:ED组合物进行包衣的不同比率中,比率9:1给出了最佳的释放曲线,包衣重量为300mg(最初5h为1.34%,24h为87%)。以9:1、8:2、7:3、6:4和5:5的不同比例进一步增加衣重至400mg导致药物释放分别为0%,0%,0%,3.47%和6.25%在最初的5小时内,分别在24小时内分别为73.52%,87.03%,92.18%,96.33%和97.61%。因此,基于体外药物释放研究的结果,发现包衣重量为400mg的7:3的比例适合于将5-氟尿嘧啶靶向结肠,而不会在胃和小肠的生理环境中释放。在40°C / 75%RH下保存3个月后,该制剂的物理外观,药物含量或体外释放模式没有变化。从开发的配方中释放出的5-氟尿嘧啶与涂料中使用的ED量成正比。 DSC和FTIR研究表明5-氟尿嘧啶与赋形剂之间没有相互作用的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号